Cancer Keys: Faecal Calprotectin

Latest from the Blog

Meet the specialists: diagnosing ovarian cancer Q&A

Meet the specialists: diagnosing ovarian cancer Q&A

15th January 2021 Missed our free GatewayC webinar on Diagnosing Ovarian Cancer? Watch our recording here. In this webinar, GatewayC met Professor Gordon Jayson, Professor of Medical Oncology at The Christie NHS Foundation Trust, who answered key questions from our...

read more

Related Posts

Cancer Keys: COVID-19 and Neutropenic Sepsis

Cancer Keys: COVID-19 and Neutropenic Sepsis

Neutropenic sepsis is a potentially fatal complication of anticancer treatment (particularly chemotherapy). Helpful hint: NICE have produced a COVID-19 rapid guideline on the delivery of systemic anticancer treatments. If patients present with COVID-19 symptoms this...

read more

Potential pitfall:

Faecal calprotectin testing is an incredibly sensitive investigation for detecting the presence of inflammation. It is raised in a wide variety of conditions including malignancy, inflammatory bowel disease and alcohol misuse. It is therefore not good at defining either the site or the cause of inflammation.

Helpful hint:

The NICE DG11 guidance recommends faecal calprotectin testing as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD), or irritable bowel syndrome (IBS), in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, if:

    • cancer is not suspected, having considered the risk factors (for example, age) described in the NICE guideline on suspected cancer and
    • appropriate quality assurance processes and locally agreed care pathways are in place for the testing.

Cancer Keys are brought to you by GatewayC.

Download this Cancer Key here

Read the NICE NG12 guidance here

Access GatewayC’s Faecal Immunochemical Test (FIT) course here

LinkedIn Twitter | Facebook